Czech/SlovakiaCzech RepublicSlovakia

Deadly delivery

09.08.2011

Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined delivery of cytostatics and therapeutic antibodies to tumours with photodynamic therapy (Bioorg Med Chem Letter, doi:10.1016/j.bmcl.2011.06.101). Their new nanocarrier consists of a cyclodextrin shell enclosing the chemotherapeutic that is attached to a zinc-porphyrin system. This accumulates in tumour cells, and can bind immuno­globulins via the 5th coordination site of the Zn complex. According to the researchers, the system can be just as readily used for a variety of therapeutic and targeting proteins, including antibodies, lectins, and HSA. The new carrier allows an attack on tumours from three fronts. Porphyrine accumulates in them, leading to photo-­oxidative tumour damage upon light activation (photodynamic therapy). Additionally, the system guides cell-toxic chemotherapeutics and cancer-selective immuno­therapeutics into tumour cells. And when tested in a mouse model with human C32 carcinoma, the coordination assembly nanosystem was shown to be therapeutically superior in terms of efficacy to the building blocks used for the construction of the system alone.

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Prague – After increasing its investment in mid-January, full-service provider CRO FGK Clinical Research GmbH has become a major shareholder in the Czech contract research organization Avemedica s.r.o. Financial details were not...

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Pilzen – German antibody drug development and discovery firm Affimed Therapeutics AG (Heidelberg) has spun-out all of its antibody discovery activities into a new Czech subsidiary – AbCheck s.r.o., which is located in Pilzen....

Czech/SlovakiaCzech RepublicSlovakia

18.09.2009

Prague/Jena – German and Czech researchers under Ales Svatos have opened the door to major improvements in the application of high-throughput metabolomics and systematic analyses of small molecules via MALDI-mass spectrometry...

Czech/SlovakiaCzech RepublicSlovakia

19.07.2009

Ceské Budejovice - The scientists from the Biology Centre of the Czech Academy of Science who coordinated the EU project MOBITAG have tabled a report on their attitudes towards political interference in the EU’s GMO authorisation...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Bratislava – According to a new study released by PG Economics, Slovak farmers would benefit more than counterparts in other EU countries from planting genetically-engineered Bt maize. Regional factors, as well as reducing an...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Vestec – The Czech Academy of Sciences and Charles University plan to build a modern biotechnology and biomedicine center, according to reports issued by the Czech Information Agency. With about 40,000 square meters of floor...

Czech/SlovakiaCzech RepublicSlovakia

13.07.2009

Olomouc – A new cluster with a focus on drug development and diagnostics has been established near Palacky University in Olmouc. Called MedChemBio, the centre seeks to attract companies with an interest in medicinal and...

Czech/SlovakiaCzech RepublicSlovakia

12.07.2009

Prague – A biotech company and a pharmaceutical enterprise are the winners of this year’s “Investor of the Year” competition, which is organised by CzechInvest and the country’s Association for Foreign Investment. At the end of...

Czech/SlovakiaCzech RepublicSlovakia

29.04.2009

Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market....

Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Displaying results 11 to 20 out of 70

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/1/article/deadly-delivery.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events